Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

Publisher: La Merie Publishing
Pages: 56
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0126
Release Date: May of 2016

250.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting epithelial growth factor receptor (EGF-R) in comparison with originator anti-EGF-R antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

Table of Contents

1.         Sales of Anti-EGF-R Antibodies

2.         Originator Anti-EGF-R Antibodies
Erbitux Approved Indications & Pipeline
Vectibix Approved Indications & Pipeline
Nimotuzumab Approved Indications & Pipeline
Portrazza Approved Indications & Pipeline

3.         Biosuperior Anti-EGF-R Antibodies
3rd Generation Anti-EGF-R Antibodies
Bispecific Anti-EGF-R Antibodies
Anti-EGF-R Antibody Drug Conjugates

4.         Biosimilar Anti-EGF-R Antibodies
Erbitux Biosimilar Antibodies:
-           Developments in Regulated Markets
-           Developments in Less Regulated Markets

5.         Corporate Anti-EGF-R Biosimilar & Biosuperior Antibody Pipelines

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up